To summarize the clinical effect of using boosters for orbital autologous fat injection transplantation.

A retrospective analysis was conducted on the clinical data of patients who underwent orbital fine autologous fat injection and transplantation at the Burn and Plastic Surgery Department of the 940th Hospital of the PLA Joint Logistics Support Force from January 2019 to December 2023. The patients were treated with orbital fine autologous fat injection and transplantation using a self-developed autologous fat transplantation booster with constant pressure and micro controllability connected to a 1 mL injector, and the therapeutic effect was analyzed.

A total of 186 patients who met the inclusion and exclusion criteria were included in this study, including 165 females and 21 males, with the average age of (39.0±7.1) years old (range: 23-71 years old). Of the 186 patients, 58 cases were of upper eyelid depression, 45 cases were of inner canthal depression, 34 cases were of ocular platform flattening, 6 cases were of meibomian depression, and 43 cases were of lacrimal groove depression. The transplantation volume of granular fat was 0.1-10 mL, with an average of 3.5 mL; the injection volume of nanofat was 0.5-2.0 mL, with an average of 0.5 mL. Follow up for 7 days to 4 years showed that 163 cases (87.6%) were satisfied with the results, 15 cases (8.1%) had average results, and 8 cases (4.3%) were dissatisfied. No surgical complications occurred.

The use of a constant pressure and micro controllable electric booster to assist autologous fat injection transplantation could achieve precision in orbital autologous fat transplantation, with high patient satisfaction, meaning that it is worthy of clinical promotion and application.